Butterfly Network Inc. stocks have been trading up by 7.11 percent following bullish coverage of its ultrasound technology potential.
Click Here for a Millionaire's POV on Trading BFLY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Midjourney Medical’s new full‑body ultrasound scanner embeds Butterfly Network’s Ultrasound‑on‑Chip modules under a co‑development and licensing deal worth up to $74M over five years.
- The Midjourney scanner uses 40 Butterfly modules per system today, with future generations expected to pack in substantially more content per unit.
- Partner Aleph Neuro used Butterfly Network’s platform to create high‑resolution, non‑invasive 3D brain images, expanding the Butterfly Embedded narrative.
- Despite these wins, BFLY shares dropped 18.8% in one session to $7.22, showing heavy selling pressure.
- A recent Form 4 filing flagged a change in beneficial ownership of Butterfly Network securities by an insider or major holder.
Live Update At 14:02:49 EDT: On Friday, June 26, 2026 Butterfly Network Inc. stock [NYSE: BFLY] is trending up by 7.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Butterfly Network, ticker BFLY, is trading like a classic high‑growth, high‑loss story that suddenly woke up. The daily chart shows BFLY launching from the low $4s in early June 2026 to the high $8s by 2026/06/26. That’s roughly a double in a few weeks, with big-range days and strong closes near the highs, signaling aggressive momentum trading.
Under the hood, the numbers still scream “early‑stage.” Butterfly Network posted about $97.6M in annual revenue and a healthy gross margin near 49.2%, but profitability remains far off. Recent quarterly figures show total revenue of $26.53M with a net loss of $12.68M and EBITDA deep in the red. Return on equity and assets are strongly negative, and free cash flow for the latest quarter was around -$14.84M.
The balance sheet, however, gives BFLY some runway. Cash and equivalents of roughly $138M, low long‑term debt (about $17.02M), and a current ratio near 4 show the company can keep funding its roadmap. For traders, that mix — strong revenue growth, big losses, and solid liquidity — often fuels sharp trend moves, both up and down, as sentiment swings between hope and fear.
More Breaking News
- MXL Stock Pops As Wall Street Bets On AI Upside
- HIVE Stock Slides As Volatility Tests Short-Term Bulls
- MRNA Stock Jumps As Flu Win And Science Day Reframe The Story
- SHPH Stock Draws Day Traders After Explosive Repricing
Intraday on 2026/06/26, the 5‑minute chart shows BFLY grinding higher from roughly $8.02 at the open to around $8.60+ by mid‑afternoon, with dips consistently bought. That pattern of higher lows throughout the session confirms near‑term bullish control, at least for now.
Why Traders Are Watching BFLY’s Licensing Momentum
The fundamental story behind BFLY’s wild chart is starting to pivot from pure hardware to leveraged licensing. Butterfly Network has long been known for handheld ultrasound and point‑of‑care imaging, mixing hardware and AI to push diagnostic tools into more hands. Now the embedded and licensing angle is taking center stage — and that is what momentum traders are circling.
The biggest piece is Midjourney Medical’s full‑body tomographic ultrasound scanner. Butterfly Network confirmed the system embeds 40 Ultrasound‑on‑Chip modules per unit under an existing co‑development and licensing deal. Management has attached a number to that opportunity: up to $74M over five years, with more upside if the platform gains wide adoption. For BFLY, that means every scanner Midjourney ships is a multiplier on module demand, and future generations are expected to use “substantially more” Butterfly content per system. That’s textbook operating leverage.
Layer on the Aleph Neuro update. Using BFLY’s Ultrasound‑on‑Chip platform, Aleph generated very high‑resolution, non‑invasive 3D brain images. That does not instantly change the income statement, but it reinforces that Butterfly Network’s chip and software stack can stretch far beyond bedside cardiac or abdominal scans. Traders love that kind of optionality — the idea that Butterfly Embedded could show up inside neuro devices, wearables, and next‑gen imaging platforms.
Despite this, the tape hasn’t been smooth. Butterfly Network shares recently fell 18.8% in a single session to $7.22, signaling traders bailing out or reacting to negative sentiment right after big news. At the same time, a Form 4 flagged a change in insider or major‑holder ownership, another ingredient for volatility even if the direction of the trade is unclear.
With management speaking at TD Cowen’s Medical Devices Emerging Growth Call Series on 2026/06/18 to discuss ultrasound‑on‑chip, software, and licensing, there is a clear near‑term catalyst. For active traders, that combination — fresh licensing headlines, proof‑of‑concepts like Aleph Neuro, and public forums to talk the story — is exactly what fuels high‑beta setups in BFLY.
Conclusion
Butterfly Network’s ticker, BFLY, now trades at the intersection of story and execution. On one side, the financials still show heavy operating losses, negative returns on capital, and a business that burns cash to grow. On the other, BFLY has cash, low leverage, and a licensing pipeline that finally comes with real numbers: a Midjourney Medical deal that may deliver up to $74M over five years and potentially more if adoption ramps.
Add the Aleph Neuro brain‑imaging milestone and the ongoing handheld ultrasound presence, and Butterfly Network suddenly looks like it has multiple ways to win — devices, embedded modules, and software‑plus‑AI. The market, though, isn’t handing out free passes. That 18.8% single‑day drop to $7.22 shows how fast sentiment on BFLY can swing, especially when insider ownership changes hit the tape and traders rush for the exits.
For short‑term traders, this is a textbook momentum name: expanding story, clean technical uptrend off the $4 base, and sharp intraday ranges. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” For longer‑term, research‑driven market participants, Butterfly Network demands close tracking of revenue mix, licensing disclosures, and cash burn quarter by quarter. As Tim Sykes likes to say, “Volatility is opportunity, but only if you respect your risk and cut losses quickly.” BFLY fits that mold — high reward potential, high risk, and a story that’s still being written.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.